Gilead inks deals with generics makers to supply COVID-19 therapy remdesivir for 127 countries
After scoring an early authorization for its COVID-19 therapy remdesivir, Gilead Sciences has been on the hunt for manufacturing partners to help boost production. Through a series of licensing agreements with generics makers, Gilead has taken the first steps to build that network.
Gilead signed nonexclusive licensing agreements with five generic drug makers operating in India and Pakistan to produce COVID-19 therapy remdesivir for 127 countries, the drugmaker said.
Gilead will work with Cipla, Mylan, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences to manufacture the drug primarily for low- and lower-middle income countries. The list also includes higher-income countries “that face significant obstacles to healthcare access,” Gilead said.
Under the agreements, Gilead will share its manufacturing know-how with the five companies to help them gear up remdesivir production. Each company will be allowed to set the price for its own generic version of the drug.
The licensed drugmakers won’t pay royalties to Gilead until the World Health Organization calls off the novel coronavirus public health emergency or until another therapy for COVID-19 is approved, Gilead said. Pfizer, which is developing a candidate with partner BioNTech, said Monday that it was evaluating the need for outsourcing production of some its drug portfolio to make way for a massive COVID-19 vaccine effort in the coming months.
Remdesivir scored an FDA emergency use nod earlier this month to treat severely ill COVID-19 patients.